Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma

Leuk Lymphoma. 2010 Jan;51(1):149-52. doi: 10.3109/10428190903275602.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Cohort Studies
  • Drug Administration Schedule*
  • Female
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / pathology
  • Male
  • Middle Aged
  • Nitrogen Mustard Compounds / administration & dosage*
  • Protease Inhibitors / administration & dosage
  • Pyrazines / administration & dosage*
  • Recurrence
  • Treatment Outcome

Substances

  • Boronic Acids
  • Nitrogen Mustard Compounds
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Bendamustine Hydrochloride